Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura cTTP
Takeda TSE 4502NYSETAK today presented favorable interim results from a global pivotal Phase 3 randomized controlled openlabel crossover trial evaluating the safety and efficacy of TAK755 recombinant ADAMTS13 replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura cTTP and pharmacokinetics PK characteristics of TAK755 as well as longterm data on TAK755 prophylaxis from a Phase 3b continuation study.
Source: businesswireindia.com
